Objective
to compare antithrombotic regimens for patients with atrial fibrillation after ACS or PCI
Study
prospective, multicentre, randomised sham-controlled, two-by-two factorial design
Population
patients with atrial fibrillation who were planning to take P2Y12 inhibitor after ACS or PCI
Endpoints
the primary outcome was major or clinically relevant nonmajor bleeding
Conclusion
in patients treated with P2Y12 inhibitor with atrial fibrillation and ACS or PCI, Apixaban instead of vitamin K antagonist and placebo instead of aspirin resulted in less bleeding
Lopes et al. N Engl J Med. 2019;380:1509-24
